Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Percentage of Participants With Objective Response

Outcome Description:

Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR). CR is defined as the disappearance of all target lesions. PR is defined as at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Outcome Time Frame:

12 months

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

Czech Republic: State Institute for Drug Control

Study ID:

A6181171

NCT ID:

NCT00684645

Start Date:

June 2008

Completion Date:

April 2011

Related Keywords:

• Metastatic Renal Cell Carcinoma
• Safety and tolerability of SUTENT® in patients with metastatic or advanced renal cell carcinoma after failure of cytokines in real-life setting.
• Carcinoma
• Carcinoma, Renal Cell

Name	Location